Avatrombopag Chemical Properties

Density 

1.440

solubility 

DMSO:27.33(Max Conc. mg/mL);42.07(Max Conc. mM)

form 

A crystalline solid

pka

3.04±0.70(Predicted)

color 

White to off-white

InChIKey

OFZJKCQENFPZBH-UHFFFAOYSA-N

SMILES

N1(C2=NC=C(C(NC3=NC(C4SC=C(Cl)C=4)=C(N4CCN(C5CCCCC5)CC4)S3)=O)C=C2Cl)CCC(C(O)=O)CC1

Avatrombopag Usage And Synthesis

Description

Avatrombopag is a medication that used for certain conditions that lead to thrombocytopenia (low platelets) such as thrombocytopenia associated with chronic liver disease in adults who are to undergo a planned medical or dental procedure.It was the third thrombopoietin receptor agonist approved for the treatment of immune thrombocytopenia and the first approved to treat periprocedural thrombocytopenia in patients with chronic liver disease (thereby providing an alternative to blood transfusions for these patients). Avatrombopag was approved for medical use in the United States in 2018, and in the European Union in 2019.

Uses

Avatrombopag is used to treat thrombocytopenia (a low number of platelets [type of blood cell needed for blood clotting]) in people with chronic (ongoing) liver disease. It is also used to treat thrombocytopenia in people with chronic immune thrombocytopenia (ITP; an ongoing condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood).

Mechanism of action

Avatrombopag is in a class of medications called thrombopoietin (TPO) receptor agonists. It works by causing the body to produce more platelets.

target

TPO receptor

IC 50

IC 50 value is 3.3 nM.

Avatrombopag(570406-98-3)Related Product Information

• Unii-4U07F515lg
• Eltrombopag
• Ibopamine Hydrochloride
• Lusutrombopag
• Lusutrombopag
• methyl 3'-amino-2'-hydroxy-[1,1'-biphenyl]-3-carboxylate
• Avatrombopag maleate
• 4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-amine